Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.52 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.52 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.45 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | CARM1 | Q86X55 | 1/20 | 0.39 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.39 |
| ▸ | PRMT8 | Q9NR22 | 1/20 | 0.39 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.39 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19750123 | 1.00 | KMT2A (0.52) | KMT2ACYP2D6HRH3HSD11B1MEN1 | |
| SCHEMBL11435054 | 1.00 | KMT2A (0.52) | KMT2ACYP2D6HRH3HSD11B1MEN1 | |
| SCHEMBL327725 | 1.00 | KMT2A (0.52) | KMT2ACYP2D6HRH3HSD11B1MEN1 | |
| SCHEMBL61193 | 1.00 | — | — | |
| SCHEMBL2107485 | 1.00 | — | — | |
| SCHEMBL24793465 | 1.00 | KMT2A (0.52) | KMT2ACYP2D6HRH3HSD11B1MEN1 | |
| SCHEMBL6506975 | 1.00 | — | — | |
| SCHEMBL944 | 1.00 | — | — | |
| SCHEMBL5990231 | 1.00 | KMT2A (0.52) | KMT2ACYP2D6HRH3HSD11B1MEN1 | |
| SCHEMBL12402455 | 1.00 | KMT2A (0.52) | KMT2ACYP2D6HRH3HSD11B1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10011616-B2 | Boron-containing small molecules as antiprotozoal1 agents | MMV MEDICINES FOR MALARIA VENTURE (CH) | 2018-07-03 | — | — | US | disclosed |
| US-20180072760-A1 | BORON-CONTAINING SMALL MOLECULES AS ANTIPROTOZOALl AGENTS | MMV MEDICINES FOR MALARIA VENTURE (CH) | 2018-03-15 | — | — | US | disclosed |
| US-20170342036-A1 | SIK INHIBITOR FOR USE IN A METHOD OF TREATING AN INFLAMMATORY AND/OR IMMUNE DISORDER | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2017-11-30 | — | — | US | disclosed |
| US-9670165-B2 | SIK inhibitor for use in a method of treating an inflammatory and/or immune disorder | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2017-06-06 | — | — | US | disclosed |
| US-7378411-B2 | Substituted thienopyrimidinones as a mitotic kinesin inhibitor | MERCK & CO., INC. (US) | 2008-05-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10011616-B2 | Boron-containing small molecules as antiprotozoal1 agents | HBS1L, DBNL, BOD1L1 | KMT2A 3286/4885CYP2D6 2886/4885HRH3 1076/4885 |
| US-20180072760-A1 | BORON-CONTAINING SMALL MOLECULES AS ANTIPROTOZOALl AGENTS | ABCB11, ABCB7, BRI3BP | KMT2A 3104/4885CYP2D6 2081/4885HRH3 1076/4885 |
| US-20170342036-A1 | SIK INHIBITOR FOR USE IN A METHOD OF TREATING AN INFLAMMATORY AND/OR IMMUNE DISORDER | SIK1, SIK2, SGK1 | KMT2A 2607/4885CYP2D6 4876/4885HRH3 1246/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.